Latest News on KOD

Financial News Based On Company


Advertisement
Advertisement

JP Morgan maintains Kodiak Sciences at Overweight, raises price target to $128 from $124

https://www.tradingview.com/news/tradingview:74235be19c3e2:0-jp-morgan-maintains-kodiak-sciences-at-overweight-raises-price-target-to-128-from-124/
JP Morgan has reiterated its "Overweight" rating for Kodiak Sciences and increased its price target for the company's stock to $128 from $124. This new price target suggests a potential upside of 30.9% from the stock's closing price on November 18. Investors can find more detailed analyst ratings and price target data for Kodiak Sciences on the Forecasts tab and within the dedicated News Flow section.

T. Rowe Price lists 2.93M Kodiak Sciences (KOD) shares but denies beneficial ownership.

https://www.stocktitan.net/sec-filings/KOD/schedule-13g-a-kodiak-sciences-inc-amended-passive-investment-disclos-7973218cbf13.html
T. Rowe Price Associates, Inc. filed an amended passive investment disclosure (SCHEDULE 13G/A) for Kodiak Sciences Inc. (KOD), reporting 2,934,560 shares, or 4.7% of the class. Despite listing these shares, T. Rowe Price Associates explicitly denied beneficial ownership, indicating that while they have sole voting and dispositive power over a significant number of shares, they do not consider themselves the beneficial owners. This filing provides key figures on sole voting power (2,930,763 shares) and sole dispositive power (2,934,560 shares) for the reported stake.

Two reporting parties list the same passive stake in Kodiak Sciences (KOD).

https://www.stocktitan.net/sec-filings/KOD/schedule-13g-a-kodiak-sciences-inc-amended-passive-investment-disclos-de29ecc9695d.html
Sirenia Capital Management LP and Alex Silverstein have each reported a passive stake of 2.9% in Kodiak Sciences Inc. (KOD), collectively owning 1,800,677 common shares. These shares are held by investment funds managed by Sirenia Capital, with Alex Silverstein serving as the managing member of Sirenia's general partner. The filing emphasizes that the reported amounts by both parties describe the identical share position.

UBS maintains Kodiak Sciences at Buy, raises price target to $150 from $120

https://www.tradingview.com/news/tradingview:f6e193cc97a82:0-ubs-maintains-kodiak-sciences-at-buy-raises-price-target-to-150-from-120/
UBS has reiterated its "Buy" rating for Kodiak Sciences and increased its price target to $150 from $120, marking a 25% hike. This new price target suggests a potential upside of 38.6% from the stock's closing price of $108.25 on November 12. Investors can find more details on price target data and analyst ratings for Kodiak Sciences on the Forecasts tab and track recommendations in the News Flow.

54% of patients in an eye-treatment trial were on six-month dosing

https://www.stocktitan.net/news/KOD/kodiak-sciences-announces-recent-business-highlights-and-third-x3zuwhnem6ey.html
Kodiak Sciences announced its Q3 2026 financial results, reporting a net loss of $66.2 million, but highlighted positive Phase 3 results for two retinal treatments: Zenkuda and tabirafusp-ted. Zenkuda met its vision endpoint in the DAYBREAK study, with 54% of patients on a six-month dosing regimen, and Kodiak plans a multi-indication Biologics License Application (BLA) for Zenkuda in Q4 2026. The company also expects pivotal results for KSI-101 in December 2026 and anticipates its cash reserves will fund operations into 2027.
Advertisement

Kodiak Sciences Inc Stock 12‑Month Price Target Raised to $129.5, Implies 20% Upside

https://www.tradingview.com/news/tradingview:6b963827029de:0-kodiak-sciences-inc-stock-12-month-price-target-raised-to-129-5-implies-20-upside/
Kodiak Sciences Inc. (KOD) has seen its average 12-month price target increased by analysts to $129.5, up from $121.67, suggesting a potential upside of approximately 20% based on recent closing prices. The consensus rating from 6 analysts remains "Buy," with 5 recommending a Buy and 1 a Hold.

Kodiak Sciences Inc. (KOD) Tops Q3 EPS by 1c

https://www.streetinsider.com/Earnings/Kodiak+Sciences+Inc.+%28KOD%29+Tops+Q3+EPS+by+1c/27337808.html
Kodiak Sciences Inc. (NASDAQ: KOD) reported its Q3 earnings per share (EPS), which came in at ($1.05). This figure was $0.01 better than the analyst estimate of ($1.06). The article provides a brief overview of the company's financial performance for the third quarter.

Kodiak Sciences CEO to present at major healthcare conferences in Nov-Dec 2026

https://pluang.com/en/news-feed/kodiak-sciences-akan-hadir-di-konferensi-investor-november-desember-2026
Kodiak Sciences Inc. announced that CEO Victor Perlroth will present at three significant investor conferences in November and December 2026. The biotech company, focused on retinal diseases, is developing late-stage clinical programs with key Phase 3 data expected by mid-2027. These presentations aim to update investors on the company's progress in developing therapeutics for a $15 billion market.

Kodiak Sciences to Present at Three Upcoming Investor Conferences

https://www.stocktitan.net/news/KOD/kodiak-sciences-to-present-at-three-upcoming-investor-9k30jn6z17jg.html
Kodiak Sciences (Nasdaq: KOD) announced that its CEO, Victor Perlroth, will present at three investor conferences in November and December 2026. He is scheduled to speak at the Jefferies Global Healthcare Conference, the UBS Global Biopharma Conference, and the 9th Annual Evercore Healthcare Conference. Live webcasts and limited-time replays of these presentations will be available on Kodiak's investor relations website.

Kodiak Sciences stock trades at 96.26 euros in late session

https://www.ad-hoc-news.de/boerse/news/corporate-news/kodiak-sciences-stock-trades-at-96-26-euros-in-late-session/70488600
Kodiak Sciences stock was quoted at 96.26 euros during Tuesday's late European session on Lang & Schwarz. This late-session quote provides investors with a reference point for monitoring the US biotechnology company's shares after regular US market hours. The indication is in euros and does not signify a fundamental change in the company's business outlook.
Advertisement

Kodiak Sciences stock hits 52-week high at 104.26 USD By Investing.com

https://in.investing.com/news/stock-market-news/kodiak-sciences-stock-hits-52week-high-at-10426-usd-93CH-5691275
Kodiak Sciences Inc. (KOD) stock has reached a new 52-week high of $104.26, driven by a 443.54% 1-year change and a 463% actual one-year price total return. Despite this impressive performance and a market capitalization of $6.47 billion, InvestingPro data suggests the stock is currently overvalued. The surge follows positive developments in its Phase 3 DAYBREAK trial and several analyst updates, with H.C. Wainwright raising its price target, Jefferies lowering its target while maintaining a Buy rating, and Goldman Sachs initiating coverage with a Neutral rating.

Kodiak Sciences (KOD) Could Be 23% Undervalued On Its Retina Pipeline Story

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-kod/kodiak-sciences/news/kodiak-sciences-kod-could-be-23-undervalued-on-its-retina-pi
Kodiak Sciences (KOD) has seen significant price appreciation, with its stock trading around $99.30, representing a 280% year-to-date return. While one narrative suggests the stock is 18% undervalued with a fair value of $121.67 due to its late-stage retina pipeline assets and upcoming BLA submission for Zenkuda, another view highlights its high price-to-book ratio of 101.9x, indicating potential valuation risk. The company's future hinges on successful trial outcomes and timely regulatory approvals for its key products.

Form 4 Kodiak Sciences Inc: BAKER BROS. ADVISORS LP (Director, 10% Owner) For: 4 November

https://uk.investing.com/news/stock-market-news/form-4-kodiak-sciences-inc-baker-bros-advisors-lp-director-10-owner-for-4-november-93CH-4966267
This article reports on a Form 4 filing for Kodiak Sciences Inc., indicating that BAKER BROS. ADVISORS LP, acting as a Director and 10% Owner, made a transaction on November 4th. The filing is a standard disclosure of insider trading activity. No specific details of the transaction are provided in the snippet.

At $98.51 a share, two funds buy Kodiak Sciences (KOD) stock.

https://www.stocktitan.net/sec-filings/KOD/form-4-kodiak-sciences-inc-insider-trading-activity-4f579e6923e6.html
Two funds, 667, L.P. and Baker Brothers Life Sciences LP, reported purchasing a total of 247,090 common shares of Kodiak Sciences Inc. (KOD) at $98.51 per share on November 4 and 5, 2026. Baker Bros. Advisors LP, acting as their investment adviser, holds complete discretion over voting and investment power for these shares. The transactions were disclosed in an SEC Form 4 filing, which notes that certain individuals and entities disclaim beneficial ownership except for their pecuniary interest.

Kodiak Sciences Inc. (KOD) Seasonal Returns Chart - Yahoo Finance

https://ca.finance.yahoo.com/quote/KOD/seasonality/
This Yahoo Finance page provides a seasonal returns chart for Kodiak Sciences Inc. (KOD), showing average monthly price returns from 2018 to 2026. It includes current stock price information, after-hours trading data, and links to other financial metrics. The primary content focuses on historical seasonality data for the company's stock.
Advertisement

Kodiak Sciences Inc. (KOD) Seasonal returns chart

https://uk.finance.yahoo.com/quote/KOD/seasonality/
The article provides a seasonal returns chart for Kodiak Sciences Inc. (KOD), displaying the average monthly price return from 2018 to 2026. It also includes current stock information, showing a slight decrease at market close and a small increase after hours. The content appears to be a stock information page from Yahoo Finance.

Kodiak Sciences stock trades at 87.33 euros in late session

https://www.ad-hoc-news.de/boerse/news/corporate-news/kodiak-sciences-stock-trades-at-87-33-euros-in-late-session/70436524
Kodiak Sciences stock traded at 87.33 euros on Lang & Schwarz during Friday's European evening session. The company, a precommercial biotechnology business, focuses on retinal medicines with its lead program, Zenkuda, having completed five Phase 3 pivotal studies. Kodiak Sciences plans to submit a multi-indication biologics license application in 2026, and its other program, KSI-501, also met primary endpoints in a Phase 3 study.

Kodiak Sciences Inc. (KOD.MX) Seasonal Returns Chart

https://ca.finance.yahoo.com/quote/KOD.MX/seasonality/
This article provides a seasonal returns chart for Kodiak Sciences Inc. (KOD.MX), showing its average monthly price return from 2020 to 2026. As of October 30, the stock was trading at 1,850.00 MXN, up 2.13%. The page also displays general market data and various financial tools available on Yahoo Finance.

Kodiak Sciences Inc. (KOD)

https://milkroad.com/assets/kod/
Kodiak Sciences Inc. (KOD) is trading at $91.32 USD, up 1.92% for the day, with a market capitalization of $5.71 billion. The stock has experienced significant volatility, with its 52-week range spanning from $15.83 to $104.00. Notable institutional investors like Jim Simons' Renaissance Technologies and Ken Griffin's Citadel Advisors hold stakes in the company, though some have recently reduced their positions.

H.C. Wainwright lifts target for Kodiak Sciences stock to USD 126

https://www.ad-hoc-news.de/boerse/news/corporate-news/h-c-wainwright-lifts-target-for-kodiak-sciences-stock-to-usd-126/70423017
H.C. Wainwright has raised its price target for Kodiak Sciences (KOD) stock from USD 96.00 to USD 126.00, maintaining a Buy rating. This new target is 38.63% above the Nasdaq price of USD 90.86, despite Kodiak Sciences reporting a second-quarter loss of USD -1.05 per share, missing consensus estimates. The company, with a market capitalization of USD 5.7 billion, is focusing on its late-stage clinical programs and plans a multi-indication biologics license application for Zenkuda in 2026.
Advertisement

Form 4 Kodiak Sciences Inc: Taiyin Yang (Director) For: 23 October

https://uk.investing.com/news/stock-market-news/form-4-kodiak-sciences-inc-taiyin-yang-director-for-23-october-93CH-4932611
This article reports on a Form 4 filing for Kodiak Sciences Inc., indicating insider transaction details involving Director Taiyin Yang. The filing pertains to activities that occurred on October 23rd. The brief announcement provides a direct update on company insider dealings.

Kodiak Sciences Inc Estimates – NASDAQ:KOD

https://www.tradingview.com/symbols/NASDAQ-KOD/financials-estimates/
This article from TradingView provides an overview of Kodiak Sciences Inc (NASDAQ: KOD) financial data and analyst estimates. It highlights reported financial data and estimates across income statements, balance sheets, cash flow statements, and valuation metrics, allowing users to compare actual results with average, high, and low estimates and visualize trends. The article is not investment advice and encourages users to conduct their own research.

After exercising $2.49 options, Kodiak Sciences (KOD) CFO sells 30,000 shares.

https://www.stocktitan.net/sec-filings/KOD/form-4-kodiak-sciences-inc-insider-trading-activity-30a9c3ee1802.html
Kodiak Sciences' CFO, John A. Borgeson, exercised options for 30,000 common shares at $2.49 each and subsequently sold all 30,000 shares on October 21, 2026. The sales, conducted under a Rule 10b5-1 trading plan adopted in September 2025, generated approximately $2.70 million in gross proceeds. Following these transactions, Borgeson holds 304,500 underlying option shares and 211,930 common shares.

Kodiak Sciences Inc. (KOD) Options Chain - Yahoo Finance

https://ca.finance.yahoo.com/quote/KOD/options/?date=1795132800&straddle=false&type=all
This Yahoo Finance page displays the options chain for Kodiak Sciences Inc. (KOD), featuring both call and put options with an expiry date of November 20, 2026. The data, delayed by 15 minutes, includes strike prices, last trade dates and times, last prices, bids, asks, and implied volatility, offering a comprehensive view of KOD's options market. The stock itself closed at 85.78, down 2.21%.

Form 144 KODIAK SCIENCES INC. For: 21 October By Investing.com

https://uk.investing.com/news/stock-market-news/form-144-kodiak-sciences-inc-for-21-october-93CH-4923678
This article from Investing.com announces the filing of Form 144 for Kodiak Sciences Inc. on October 21. Form 144 is a notice of the intent to sell restricted securities, indicating potential insider activity. The brief report highlights the date of the filing and the associated company.
Advertisement

Form 144 KODIAK SCIENCES INC. For: 21 October By Investing.com

https://in.investing.com/news/stock-market-news/form-144-kodiak-sciences-inc-for-21-october-93CH-5646446
This article announces the filing of Form 144 for Kodiak Sciences Inc. for October 21st. Form 144 indicates an intent to sell restricted or control securities. The article provides this basic information along with a stock market context.

Form 144 KODIAK SCIENCES INC. For: 21 October By Investing.com

https://za.investing.com/news/stock-market-news/form-144-kodiak-sciences-inc-for-21-october-93CH-4517726
This article reports on a Form 144 filing by Kodiak Sciences Inc. (KOD) for October 21. Form 144 is a notice of the intent to sell restricted securities. The brief notice indicates a transaction related to the company on the specified date.

Form 144 KODIAK SCIENCES INC. For: 21 October By Investing.com

https://ng.investing.com/news/stock-market-news/form-144-kodiak-sciences-inc-for-21-october-93CH-2749603
This article announces the filing of Form 144 for Kodiak Sciences Inc. on October 21. Form 144 is a notice of the intent to sell restricted securities. The brief notice highlights the company's stock activity, including a +2.16% change.

Form S-3ASR Kodiak Sciences Inc For: 20 October By Investing.com

https://ng.investing.com/news/stock-market-news/form-s3asr-kodiak-sciences-inc-for-20-october-93CH-2747179
This article reports on Kodiak Sciences Inc.'s filing of a Form S-3ASR for October 20. The brief financial notice highlights the company's stock symbol KOD and its stock performance. The filing is a standard regulatory disclosure.

Kodiak Sciences Inc. (KOD) files mixed shelf

https://www.streetinsider.com/Corporate+News/Kodiak+Sciences+Inc.+%28KOD%29+files+mixed+shelf/27211349.html
Kodiak Sciences Inc. (NASDAQ: KOD) has filed a mixed shelf offering, which includes common stock, preferred stock, debt securities, warrants, and units. The company's stock is currently priced at $92.97, up 1.77%, with an overall analyst rating of SELL.
Advertisement

Form S-3ASR Kodiak Sciences Inc For: 20 October By Investing.com

https://za.investing.com/news/stock-market-news/form-s3asr-kodiak-sciences-inc-for-20-october-93CH-4515304
This article announces the filing of Form S-3ASR by Kodiak Sciences Inc. for October 20. It briefly notes Kodiak Sciences' stock symbol (KOD) and its percentage change. The content primarily serves as an announcement rather than providing in-depth financial analysis.

KOD Stock Explodes As Zenkuda Trial Data Rewire Wall Street

https://www.timothysykes.com/news/kodiak-sciences-inc-kod-news-2026_10_19/
Kodiak Sciences Inc. (KOD) stock surged over 7.91% after positive Phase 3 DAYBREAK trial data for its eye drug Zenkuda. The trial met primary endpoints, showing non-inferior vision gains, strong durability, and a favorable safety profile compared to existing treatments, leading to significantly raised price targets by major financial firms. Despite the company still being in a development stage with negative EBITDA, the successful trial de-risks the drug, positioning it for potential regulatory submissions in late 2026 and a commercial launch by 2027.

H.C. Wainwright raises Kodiak Sciences stock target to USD 126.00

https://www.ad-hoc-news.de/boerse/news/nebenwerte/h-c-wainwright-raises-kodiak-sciences-stock-target-to-usd-126-00/70351468
H.C. Wainwright has increased its price target for Kodiak Sciences (KOD) to $126.00, up from $96.00, while maintaining a Buy rating. This new target is 46.94% above Kodiak's recent closing price of $85.75. The company's next earnings report is scheduled for November 12, 2026, and its clinical pipeline is focused on retinal diseases.

How Investors May Respond To Kodiak Sciences Stock After Wet AMD Trial Success

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-kod/kodiak-sciences/news/how-investors-may-respond-to-kodiak-sciences-stock-after-wet
Kodiak Sciences reported positive late-stage clinical data for its wet AMD treatments, Zenkuda and tabirafusp ted, showing non-inferior vision gains compared to aflibercept. This success puts Kodiak's pipeline in direct competition with existing standards of care, which could influence future commercialization and pricing strategies. Despite a significant stock price increase and positive trial results, the company still faces financial challenges due to its lack of commercial revenue and high cash burn, making regulatory and payer responses crucial for its future funding and valuation.

Kodiak Sciences Inc. (KOD) options chain

https://au.finance.yahoo.com/quote/KOD/options/?date=1799971200&straddle=false&type=all
This article provides detailed options chain data for Kodiak Sciences Inc. (KOD) as of October 16, 2026. It includes information for both call and put options with a January 15, 2027 expiration date, showing strike prices, last trade details, bid/ask prices, changes, volume, open interest, and implied volatility. The stock closed at $85.75, down 2.69%, with after-hours trading at $85.05.
Advertisement

HC Wainwright raises target for Kodiak Sciences stock to USD 126.00

https://www.ad-hoc-news.de/boerse/news/nebenwerte/hc-wainwright-raises-target-for-kodiak-sciences-stock-to-usd-126-00/70332671
HC Wainwright has increased its price target for Kodiak Sciences (KOD) stock from $96.00 to $126.00, maintaining a "Buy" rating. This adjustment comes despite Kodiak reporting a Q2 2026 loss of $1.05 per share, which missed analyst consensus. The company's stock was trading up by 6.63% on Nasdaq, and its next earnings report for Q3 2026 is anticipated on November 12, 2026.

KOD Stock Rockets As DAYBREAK Trial Rewrites Biotech Expectations

https://www.timothysykes.com/news/kodiak-sciences-inc-kod-news-2026_10_15/
Kodiak Sciences Inc (KOD) shares surged after its Zenkuda and tabirafusp-ted drugs met Phase 3 endpoints in the DAYBREAK trial for wet age-related macular degeneration (wet AMD), demonstrating non-inferiority to Eylea with stronger durability. This breakthrough led to significant price target increases from major banks and analysts, positioning KOD as a high-beta clinical story for traders despite its pre-revenue status and cash burn. The company plans regulatory submissions for Zenkuda in Q4 2026, targeting a potential wet AMD launch by year-end 2027.

KOD Stock Soars As Zenkuda Trial Fuel Sparks Massive Re‑Rating

https://stockstotrade.com/news/kodiak-sciences-inc-kod-news-2026_10_15/
Kodiak Sciences Inc (KOD) shares surged after its Phase 3 DAYBREAK trial for Zenkuda and tabirafusp-ted in wet age-related macular degeneration met primary endpoints, showing non-inferior vision gains, strong durability, and a favorable safety profile. This positive data led to multiple analyst price target increases and positions Kodiak for regulatory submissions in Q4 2026 and a potential launch in late 2027. The company's financial overview shows it's a clinical-stage biotech with significant R&D spending, trading heavily on trial data and headlines.

KOD Stock Rockets As DAYBREAK Trial Rewrites Biotech Expectations

https://timothysykes.com/news/kodiak-sciences-inc-kod-news-2026_10_15/
Kodiak Sciences Inc (KOD) shares surged after its Zenkuda and tabirafusp-ted drugs met Phase 3 endpoints in the DAYBREAK trial for wet age-related macular degeneration (wet AMD), showing non-inferiority to Eylea with stronger durability. This breakthrough led to significant price target increases from major banks and is expected to result in regulatory submissions in Q4 2026 with a potential launch in late 2027. The company's stock has seen a massive re-rating, transforming it into a high-beta clinical story despite its pre-revenue status.

HC Wainwright & Co. maintains Buy rating on Kodiak Sciences, $126 price target

https://www.tradingview.com/news/tradingview:7e644a5545baa:0-hc-wainwright-co-maintains-buy-rating-on-kodiak-sciences-126-price-target/
HC Wainwright & Co. has reiterated its Buy rating on Kodiak Sciences (KOD) and set a price target of $126.00, suggesting a 26.2% upside from the recent closing price. This positive outlook is driven by successful Phase 3 clinical trial results for Zenkuda and KSI-501 in wet AMD, which showed comparable efficacy to standard treatments. The firm also highlighted the strong market potential for Kodiak's investigational bispecific therapies, KSI-501 and KSI-101, designed to address unmet needs in retinal diseases.
Advertisement

H.C. Wainwright raises Kodiak Sciences stock price target on trial data

https://ca.investing.com/news/stock-market-news/hc-wainwright-raises-kodiak-sciences-stock-price-target-on-trial-data-93CH-4875971
H.C. Wainwright increased its price target for Kodiak Sciences Inc. (NASDAQ:KOD) to $126 from $96, maintaining a Buy rating, following positive Phase 3 DAYBREAK trial results for Zenkuda and Tabirafusp in wet age-related macular degeneration. The trial met its primary endpoint for visual acuity non-inferiority, with Zenkuda showing rapid and sustained retinal drying and impressive durability. Kodiak Sciences plans to submit a Biologics License Application in Q4 2026.

H.C. Wainwright raises Kodiak Sciences stock price target on trial data

https://www.investing.com/news/analyst-ratings/hc-wainwright-raises-kodiak-sciences-stock-price-target-on-trial-data-93CH-4944140
H.C. Wainwright increased its price target for Kodiak Sciences Inc. (NASDAQ: KOD) to $126 from $96, maintaining a Buy rating after positive Phase 3 DAYBREAK trial results for Zenkuda and Tabirafusp were presented. The trial achieved its primary endpoint for wet age-related macular degeneration, showing strong efficacy and durability. Kodiak Sciences plans to submit a Biologics License Application in Q4 2026.

Kodiak Sciences Rises as Investors Focus on Fresh Clinical Visibility After Phase 3 Win

https://www.moomoo.com/news/post/1000869841/kodiak-sciences-rises-as-investors-focus-on-fresh-clinical-visibility
Kodiak Sciences (KOD) saw its stock rise after the company announced positive Phase 3 results for its drug tarcocimab in diabetic macular edema (DME). This clinical success provides much-needed visibility for investors, positioning the company for potential regulatory approval and market entry. The positive trial outcome has led to increased investor confidence, as reflected in the stock's performance.

Kodiak Sciences Inc. (KOD) stock price, news, quote and history

https://sg.finance.yahoo.com/quote/KOD/
This article provides a comprehensive overview of Kodiak Sciences Inc. (KOD) stock, including its current price, historical data, financial performance, and analyst ratings. Kodiak Sciences is a clinical-stage biopharmaceutical company focused on developing therapeutics for retinal diseases, with lead product candidates like tarcocimab tedromer. The company's stock has shown significant returns over the past year, and analysts have issued "Buy" ratings with updated price targets.

Kodiak Sciences Rises as Investors Focus on Fresh Clinical Visibility After Phase 3 Win

https://www.quiverquant.com/news/Kodiak+Sciences+Rises+as+Investors+Focus+on+Fresh+Clinical+Visibility+After+Phase+3+Win
Kodiak Sciences (KOD) saw its stock rise by 6.4% due to renewed investor attention on its retina pipeline, especially as it prepares to present Phase 3 DAYBREAK results at AAO 2026. The company's recent data showed its Zenkuda and KSI-501 treatments met primary endpoints in wet AMD, keeping it on track for a planned Zenkuda BLA filing in Q4 2026. Insider trading data indicates significant purchases by BROS. ADVISORS LP BAKER, while institutional investors show mixed activity with major additions by T. ROWE PRICE INVESTMENT MANAGEMENT, INC. and PRICE T ROWE ASSOCIATES INC /MD/.
Advertisement

How Investors May Respond To Kodiak Sciences Stock As Phase 3 Eye Drug Results Land

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-kod/kodiak-sciences/news/how-investors-may-respond-to-kodiak-sciences-stock-as-phase
Kodiak Sciences reported positive Phase 3 DAYBREAK study results for its eye drugs Zenkuda and tabirafusp-ted, meeting primary endpoints for wet AMD with vision gains comparable to aflibercept and good safety. The company plans to submit regulatory filings for multiple indications, concentrating potential revenue drivers. Despite these clinical successes, Kodiak Sciences currently has no revenue, reports significant losses, and faces a volatile stock price and a capital-intensive business model.

How Investors May Respond To Kodiak Sciences Stock As Phase 3 Eye Drug Results Land

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-kod/kodiak-sciences/news/how-investors-may-respond-to-kodiak-sciences-stock-as-phase/amp
Kodiak Sciences reported positive Phase 3 results for its eye drugs Zenkuda and tabirafusp-ted, meeting primary endpoints in wet AMD. The company plans multiple regulatory submissions and presentations at AAO 2026, consolidating several potential revenue drivers. Despite these clinical successes, Kodiak Sciences currently reports no revenue, significant losses, and a history of shareholder dilution, with its stock experiencing high volatility.

Is Kodiak Sciences (KOD) Fully Valued As AAO 2026 Trial Data Nears?

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-kod/kodiak-sciences/news/is-kodiak-sciences-kod-fully-valued-as-aao-2026-trial-data-n
Kodiak Sciences (KOD) is gaining attention as Phase 3 data for Zenkuda, tabirafusp-ted, and early-stage KSI-101 will be presented at the AAO 2026 ophthalmology meeting. Despite recent short-term dips, the stock has seen significant year-to-date gains, prompting questions about its current valuation. While some analyses suggest the stock is overvalued at $91.08 compared to a fair value of $85, other models point to a much higher potential future cash flow value of $737.08, indicating a wide disparity in valuation perspectives.

Kodiak Sciences stock heads into AAO data on October 9

https://www.ad-hoc-news.de/boerse/news/nebenwerte/kodiak-sciences-stock-heads-into-aao-data-on-october-9/70261388
Kodiak Sciences (KOD) is approaching significant clinical data presentations at AAO 2026 for its three late-stage programs, including DAYBREAK, GLOW2, and APEX. The company's stock closed at $91.08, down 1.36% on October 7, 2026, while its Q2 loss widened to $65.6 million. Despite a "Moderate Buy" consensus from analysts with an average target of $100.43, the company faces execution and regulatory risks as it remains precommercial.

Kodiak Sciences to Present Clinical Data Across All Three Late-Stage Programs at AAO 2026

https://www.moomoo.com/news/post/1000688667/kodiak-sciences-to-present-clinical-data-across-all-three-late
Kodiak Sciences announced it will present clinical data from all three of its late-stage programs at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting. The presentations will cover data from the BEACON, GLOW, and DAYLIGHT studies, focusing on the company's investigational therapies for various retinal diseases. This highlights Kodiak's progress and commitment to advancing its pipeline.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement